Multiple Sclerosis Market is Expected to Surpass USD 33 Billion by 2036, Driven by Rising Disease Burden and Emerging BTK Inhibitor Therapies | DelveInsight

The Multiple Sclerosis Market is witnessing substantial growth driven by the increasing diagnosed prevalence of the disease, growing adoption of high-efficacy disease-modifying therapies, advancements in treatment delivery systems, and the emergence of novel therapies targeting progressive forms of multiple sclerosis. Additionally, the launch of emerging therapies such as Remibrutinib, Tolebrutinib and Frexalimab, Fenebrutinib, and others will further boost the Multiple Sclerosis market growth.
DelveInsight, a leading market research and consulting firm, has released its latest report, "Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast-2036." The report provides an in-depth understanding of Multiple Sclerosis, including historical and forecasted epidemiology, market trends, treatment landscape, emerging therapies, market size, market share, and industry outlook across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Multiple Sclerosis Market

*
The Multiple Sclerosis market size in the 7MM is expected to increase significantly during the forecast period 2022-2036.

*
The total Multiple Sclerosis market size in the 7MM was approximately USD 19.6 billion in 2022 and is projected to reach nearly USD 33.1 billion by 2036.

*
In 2025, the total diagnosed prevalent cases of Multiple Sclerosis across the 7MM were estimated at approximately 1.7 million cases and are expected to increase during the forecast period.

*
The United States accounted for the highest Multiple Sclerosis market size among the 7MM, representing approximately USD 17 billion in 2025.

*
Germany represented the largest Multiple Sclerosis market among EU4 and the UK, accounting for approximately USD 1.6 billion in 2025.

*
The United States accounted for nearly 56% of the diagnosed prevalent patient pool in the 7MM, followed by EU4 and the UK with approximately 42%.

*
Females represented approximately 72% of diagnosed Multiple Sclerosis cases in Germany in 2025, highlighting a significant gender disparity in disease prevalence.

*
In the United Kingdom, Relapsing-Remitting Multiple Sclerosis (RRMS) accounted for the highest phenotype-specific diagnosed prevalent population, with approximately 85 thousand cases in 2025.

*
Leading Multiple Sclerosis companies such as Novartis, Sanofi, Roche, Genentech, Immunic Therapeutics, AB Science, Clene Nanomedicine, InnoCare Pharma, and others are developing novel Multiple Sclerosis treatments.

*
Promising Multiple Sclerosis drugs in the pipeline include Remibrutinib, Tolebrutinib, Fenebrutinib, Frexalimab, Vidofludimus Calcium (IMU-838), Masitinib, CNM-Au8, Orelabrutinib, and others.

Keen to know more about the market? Request our sample page at Multiple Sclerosis Market Report.

https://www.delveinsight.com/sample-request/multiple-sclerosis-market [https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Key Factors Driving the Multiple Sclerosis Market

Rising Diagnosed Prevalence and Improved Disease Recognition

Growing awareness, improved diagnostic techniques, enhanced MRI accessibility, and broader healthcare access are leading to earlier diagnosis and treatment initiation. Increasing prevalence rates across major markets continue to support the expansion of the Multiple Sclerosis treatment market.

Increasing Adoption of High-Efficacy Disease-Modifying Therapies

The Multiple Sclerosis treatment landscape has evolved significantly with the introduction of advanced DMTs. High-efficacy therapies such as OCREVUS, KESIMPTA, BRIUMVI, MAYZENT, MAVENCLAD, VUMERITY, and others are increasingly being adopted due to their ability to reduce relapse rates and delay disability progression.

Growing Focus on Progressive Multiple Sclerosis

Current therapies primarily target inflammatory disease activity, while progressive Multiple Sclerosis remains an area of high unmet need. Emerging BTK inhibitors and neuroprotective therapies are expected to transform treatment paradigms by targeting underlying neurodegeneration and chronic neuroinflammation.

Advancements in Treatment Convenience and Delivery

Innovations in treatment administration, including subcutaneous formulations and home-based therapies, are improving patient convenience and adherence. The approval of OCREVUS ZUNOVO represents a major advancement in treatment delivery for relapsing and progressive Multiple Sclerosis.

Multiple Sclerosis Competitive Landscape

Several Multiple Sclerosis therapies are currently marketed, including OCREVUS and OCREVUS ZUNOVO (Roche), KESIMPTA (Novartis), BRIUMVI (TG Therapeutics), MAYZENT (Novartis), VUMERITY (Biogen), MAVENCLAD (Merck KGaA), and ZEPOSIA (Bristol Myers Squibb). These therapies help reduce relapse rates, slow disease progression, and improve long-term patient outcomes.

The emerging Multiple Sclerosis pipeline includes promising therapies such as Remibrutinib, Tolebrutinib, Fenebrutinib, Frexalimab, Vidofludimus Calcium (IMU-838), Masitinib, CNM-Au8, and Orelabrutinib. These candidates target novel mechanisms including BTK inhibition, immune modulation, neuroprotection, and remyelination, aiming to improve efficacy and address unmet needs, particularly in progressive forms of Multiple Sclerosis.

Discover more about therapies set to grab major Multiple Sclerosis market share @ Multiple Sclerosis Treatment Landscape. [https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Recent Developments in the Multiple Sclerosis Market

*
In December 2025, the FDA issued a Complete Response Letter for Tolebrutinib in non-relapsing secondary progressive Multiple Sclerosis.

*
In November 2025, Roche announced that Fenebrutinib met the primary endpoint in the Phase III FENhance 2 trial, significantly reducing annualized relapse rates compared with teriflunomide.

*
In June 2025, Immunic Therapeutics reported positive long-term extension results from the Phase II EMPhASIS trial evaluating Vidofludimus Calcium in RRMS patients.

*
In September 2025, Clene Nanomedicine presented data demonstrating improved brain energy metabolism with CNM-Au8 in Multiple Sclerosis patients.

*
In September 2024, the FDA approved OCREVUS ZUNOVO as the first subcutaneous formulation of ocrelizumab for adults with relapsing and progressive Multiple Sclerosis.

What is Multiple Sclerosis?

Multiple Sclerosis is a chronic autoimmune neurological disorder in which the immune system attacks the protective myelin sheath surrounding nerve fibers in the central nervous system. The disease disrupts communication between the brain and the body, resulting in symptoms such as fatigue, muscle weakness, visual disturbances, cognitive impairment, balance issues, and walking difficulties. Multiple Sclerosis can manifest as Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), or Primary Progressive Multiple Sclerosis (PPMS).

Multiple Sclerosis Epidemiology Segmentation

The Multiple Sclerosis epidemiology section provides insights into the historical and current patient pool and forecasted trends across the 7MM and includes:

*
Total Diagnosed Prevalent Cases of Multiple Sclerosis

*
Gender-specific Diagnosed Prevalent Cases of Multiple Sclerosis

*
Pediatric and Adult Diagnosed Cases of Multiple Sclerosis

*
Phenotype-specific Diagnosed Cases of Multiple Sclerosis

*
EDSS-specific Diagnosed Cases of Multiple Sclerosis

Scope of the Multiple Sclerosis Market Report

*
Therapeutic Assessment: Multiple Sclerosis marketed and emerging therapies

*
Multiple Sclerosis Market Dynamics: Key market drivers, barriers, opportunities, and trends

*
Key Companies: Novartis, Sanofi, Roche, Genentech, Immunic Therapeutics, AB Science, Clene Nanomedicine, InnoCare Pharma, and others

*
Key Therapies: OCREVUS, OCREVUS ZUNOVO, KESIMPTA, BRIUMVI, MAYZENT, MAVENCLAD, Remibrutinib, Tolebrutinib, Fenebrutinib, Frexalimab, Vidofludimus Calcium, CNM-Au8, Masitinib, and others

*
Competitive Intelligence Analysis: SWOT analysis and market entry strategies

*
Unmet Needs, KOL Views, Analyst Perspectives, Market Access and Reimbursement Analysis

To know more about Multiple Sclerosis companies working in the treatment market, visit @ Multiple Sclerosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Table of Contents

*
Multiple Sclerosis Market Report Introduction

*
Executive Summary for Multiple Sclerosis

*
SWOT Analysis of Multiple Sclerosis

*
Multiple Sclerosis Patient Share (%) Overview at a Glance

*
Multiple Sclerosis Market Overview at a Glance

*
Multiple Sclerosis Disease Background and Overview

*
Multiple Sclerosis Epidemiology and Patient Population

*
Country-Specific Patient Population of Multiple Sclerosis

*
Multiple Sclerosis Current Treatment and Medical Practices

*
Multiple Sclerosis Unmet Needs

*
Multiple Sclerosis Emerging Therapies

*
Multiple Sclerosis Market Outlook

*
Country-Wise Multiple Sclerosis Market Analysis (2022-2036)

*
Multiple Sclerosis Market Access and Reimbursement

*
Multiple Sclerosis Market Drivers

*
Multiple Sclerosis Market Barriers

*
Multiple Sclerosis Appendix

*
Multiple Sclerosis Report Methodology

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=multiple-sclerosis-market-is-expected-to-surpass-usd-33-billion-by-2036-driven-by-rising-disease-burden-and-emerging-btk-inhibitor-therapies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.